WHO Sounds Alert Over Critical Lack of Obesity Medications
Under 10% of people that would benefit from obesity jabs such as Wegovy can access them, warns the global health agency as it releases its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for increased and just access to this class of drugs.
According to forecasts, over two billion could be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that excess weight is a long-term condition that can be addressed with thorough and ongoing support," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key obstacles to widespread availability to the jabs that can assist patients in reducing considerable body mass, notes the agency.
Weight-Loss Drug Shortage
Even under the present most favorable case, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of those who need them, according to the WHO.
The recommendation urges governments and firms to widen availability, via measures like patent sharing.
The intellectual property rights on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a natural hormone to slow digestion, reduce hunger and enhance the sense of being full so users consume fewer calories.
Individuals typically start to lose weight within a few weeks of commencing the weekly injections.
Studies indicates people may see weight return within a year of stopping the drug, when their typical hunger come back.
Being carrying excess weight elevates your risk for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and certain malignancies.
Excess weight impacts individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
